Breaking News Bar

Business News and Information

Epizyme to Present at World Epigenetics Summit and Convergence Forum West

Epizyme, Inc., a company leading the discovery and development of personalized therapeutics for genetically-defined cancer patients, today announced its participation in two upcoming conferences.

Robert A. Copeland, Ph.D., Executive Vice President and Chief Scientific Officer, will present at the 2nd World Epigenetics Summit being held in Munich, Germany. Dr. Copeland’s presentation, titled, “Protein Methyltransferase Inhibitors as Personalised Cancer Therapeutics,” will take place on December 7, 2011 at 12:20pm. The presentation will cover the disease relevance of the histone methyltransferase enzyme target class and will also provide an overview of Epizyme’s DOT1L inhibitor program as an example of a drug development effort focused on this class.

Robert J. Gould, Ph.D., President and Chief Executive Officer, will moderate the opening session of the Convergence Forum West being held in San Francisco, CA. The session, titled, “Accessing Innovation, Inside & Outside the Corporate Walls,” will take place on December 8, 2011, at 1:45pm.

Epizyme’s therapeutics programs are focused on histone methyltransferases, a class of epigenetic enzymes that play an important role in regulating pathways of genes that are strongly associated with the underlying causes of many human diseases, including cancer. Epizyme announced a program-based partnership with Eisai for the epigenetic enzyme EZH2 in March 2011 and a multi-target drug discovery alliance with GlaxoSmithKline in January 2011, and also receives funding support from the Multiple Myeloma Research Foundation (MMRF) and the Leukemia & Lymphoma Society (LLS).

About Epizyme

Epizyme is leading the discovery and development of small molecule histone methyltransferase (HMT) inhibitors, a new class of personalized therapeutics for the treatment of genetically-defined cancer patients based on breakthroughs in the field of epigenetics. Genetic alterations in the HMTs are strongly associated with the underlying causes of multiple human diseases, including cancer. Epizyme’s patient-driven approach represents the future of personalized therapeutics by creating better medicines for the right patients more quickly and at lower cost than traditional approaches.


MacDougall Biomedical Communications
Kari Watson or Jennifer Conrad, 781-235-3060

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear